11 recruiting, 7 completed, 5 active not recruiting, 2 withdrawn. 26 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 26 | Recruiting 11, Completed 7, Active not recruiting 5, Withdrawn 2, Unknown 1 |
| Phase 1 | 2 | Completed 1, Recruiting 1 |
| Phase 3 | 1 | Completed 1 |
Follow Oropharynx Cancer: new trials by email Literature Review of Oropharynx Cancer trials Research Report on Oropharynx Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers E7 TCR-T cells, Aldesleukin - HPV-Associated Cervical Carcinoma, HPV-Related Carcinoma | Phase 1 / Phase 2 | Recruiting | Christian Hinrichs | 15 | 2025-08-11 | 2026-10-28 |
| Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest United States Population Celecoxib, Erlotinib Hydrochloride, Imaging Procedure - Metastatic Oral Cavity Carcinoma, Recurrent Oral Cavity Carcinoma | Phase 2 | Recruiting | Mayo Clinic | 25 | 2025-08-07 | 2026-10-01 |
| A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC) Sacituzumab Govitecan, Cetuximab - Squamous Cell Carcinoma of Head and Neck, Sinus Cancer | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 40 | 2025-07-02 | 2026-02-19 |
| Personalized Volume-deescalated Elective Nodal Irradiation in Oropharyngeal Head and Neck Squamous Cell Carcinoma De-escalation of irradiated volume - Oropharynx Cancer | Phase 2 | Recruiting | University of Zurich | 120 | 2025-02-04 | 2026-10-08 |
| Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL) Experimental Observation, Observation per Standard of Care, Adjuvant Treatment per Standard of Care - Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma | Phase 2 | Recruiting | University of Maryland, Baltimore | 61 | 2024-03-07 | 2025-11-10 |
| Neoadjuvant Immunoradiotherapy With Evorpacept and Pembrolizumab in HPVOPC (Human Papilloma Virus Oropharynx Cancer) Evorpacept - Oropharynx Cancer | Phase 2 | Active not recruiting | University of California, San Diego | 28 | 2024-02-23 | 2026-07-16 |
| Trial of Individualized Adaptive RT in HPV-related High Risk Oropharynx Cancer Radiation, Platinum based chemotherapy - Oropharynx Cancer, HPV-Related Carcinoma | Phase 2 | Active not recruiting | University of Michigan Rogel Cancer Center | 19 | 2023-12-20 | 2026-05-18 |
| Lymphoscintigraphy Directed Elective Neck Radiation for p16+ Favorable Risk Oropharynx Cancer Radiation therapy (5 days for 7 weeks), Radiation therapy (5 days for 6 weeks), Cisplatin - Oropharynx Cancer | Phase 2 | Recruiting | Fox Chase Cancer Center | 22 | 2023-03-14 | 2026-11-02 |
| E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers E7 TCR-T cells, Aldesleukin - Cervical Cancer, Throat Cancer | Phase 2 | Recruiting | Christian Hinrichs | 20 | 2023-03-07 | 2026-10-28 |
| Phase 2 Study of Neoadjuvant SAR444245 Plus Cemiplimab in HPV Related Oropharynx Squamous Cell Carcinoma SAR444245, Cemiplimab - Squamous Cell Carcinoma, Oropharynx Cancer | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2022-08-24 | 2023-09-13 | |
| Transoral Surgical Resection Followed by De-escalated Adjuvant IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer therapeutic conventional surgery, laboratory biomarker analysis, quality-of-life assessment - Oropharynx Cancer | Phase 2 | Recruiting | Heath Skinner | 150 | 2022-07-20 | 2026-07-21 |
| A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC) HPV ctDNA Assay, MRI Studies, EORTC QLQ H&N 35 and C30 - HPV, Oropharynx Cancer | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 30 | 2022-03-24 | 2026-04-13 |
| Adaptive RadioTherapy for OroPharynx Cancer Standard radiotherapy +/- chemotherapy, Experimental radiotherapy +/- chemotherapy - Oropharynx Cancer, Radiotherapy; Complications | Phase 2 | Recruiting | Centre hospitalier de l'Université de Montréal (CHUM) | 120 | 2021-07-30 | 2026-08-24 |
| Selective Avoidance of Nodal VolumEs at Minimal Risk (GCC 20110) Intensity modulated radiotherapy (IMRT)/volumetric modulated arc therapy (VMAT) or Pencil beam proton therapy (PBPT) - Head and Neck Cancer, Oropharynx Cancer | Phase 2 | Active not recruiting | University of Maryland, Baltimore | 52 | 2021-03-01 | 2026-08-12 |
| Testing Less Intensive Radiation With Chemotherapy to Treat Low-risk Patients With HPV-positive Oropharyngeal Cancer Cisplatin injection - Cancer of the Head and Neck, Oropharynx Cancer | Phase 2 | Recruiting | University of Missouri-Columbia | 28 | 2020-09-28 | 2024-05-17 |
| Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients MEDI0457, Durvalumab - HPV Positive Oropharyngeal Squamous Cell Carcinoma, Oropharynx Cancer | Phase 2 | Withdrawn | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2019-09-17 | 2022-07-29 | |
| Feasibility and Tolerance of Nivolumab Neoadjuvant Immunotherapy in High Risk HPV Driven Oropharynx Cancer Nivolumab, Chemoradiation - Oropharynx Cancer | Phase 2 | Completed | UNICANCER | 62 | 2019-07-25 | 2025-03-04 |
| Neoadjuvant Chemotherapy and Transoral Robotic Surgery for Oropharyngeal Cancer. Docetaxel - Oropharynx Cancer, Tonsil Cancer | Phase 2 | Unknown | Nader Sadeghi | 60 | 2018-08-14 | 2023-10-23 |
| Individualized Adaptive De-escalated Radiotherapy for HPV-related Oropharynx Cancer Carboplatin, Radiation Therapy, Paclitaxel - Oropharynx Cancer | Phase 2 | Completed | University of Michigan Rogel Cancer Center | 91 | 2018-05-21 | 2026-08-07 |
| Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer Pembrolizumab, Radiation therapy, Cisplatin - Head and Neck Squamous Cell Carcinoma, Cancer | Phase 2 | Active not recruiting | Loren Mell, MD | 126 | 2018-03-15 | 2025-10-07 |
Showing 20 of 26. Sign in to see all of them.
Oropharyngeal Neoplasms (26) · Head and Neck Neoplasms (10) · Squamous Cell Carcinoma of Head and Neck (8) · Mouth Neoplasms (7) · Laryngeal Neoplasms (6) · Hypopharyngeal Neoplasms (5) · Carcinoma, Squamous Cell (3) · Neoplasm Metastasis (3) · Anus Neoplasms (2) · Nasopharyngeal Neoplasms (2) · Penile Neoplasms (2) · Recurrence (2) · Uterine Cervical Neoplasms (2) · Vaginal Neoplasms (2) · Vulvar Neoplasms (2)
Neoplasms by Site (26) · Neoplasms (25) · Otorhinolaryngologic Diseases (25) · Otorhinolaryngologic Neoplasms (25) · Pharyngeal Diseases (25) · Pharyngeal Neoplasms (25) · Stomatognathic Diseases (25) · Head and Neck Neoplasms (16) · Neoplasms by Histologic Type (11) · Carcinoma (10) · Neoplasms, Glandular and Epithelial (10) · Carcinoma, Squamous Cell (7) · Mouth Diseases (7) · Laryngeal Diseases (6) · Respiratory Tract Diseases (6)
Cisplatin (9) · Carboplatin (4) · Radiotherapy, Intensity-Modulated (4) · Radiotherapy (3) · Adoptive Transfer (2) · Cetuximab (2) · Chemoradiotherapy (2) · Docetaxel (2) · Fluorouracil (2) · Radiation (2) · aldesleukin (2) · durvalumab (2) · pembrolizumab (2) · 130-nm albumin-bound paclitaxel (1) · ALX148 (1)
Memorial Sloan Kettering Cancer Center (3) · Christian Hinrichs (2) · M.D. Anderson Cancer Center (2) · University of California, San Diego (2) · University of Maryland, Baltimore (2) · University of Michigan Rogel Cancer Center (2) · Centre hospitalier de l'Université de Montréal (CHUM) (1) · Fox Chase Cancer Center (1) · Gustave Roussy, Cancer Campus, Grand Paris (1) · Heath Skinner (1) · Loren Mell, MD (1) · Mayo Clinic (1) · Nader Sadeghi (1) · Orlando Guntinas-Lichius, Prof. Dr. med. (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1)
United States (20) · Canada (2) · France (2) · Australia (1) · Germany (1) · Switzerland (1)
Christian S Hinrichs, MD (2) · Acharf Shamseddine, MD (1) · Assuntina Sacco, M.D. (1) · C. Jillian Tsai, MD (1) · Carole Fakhry, MD, MPH (1) · Gary B. Gunn, MD (1) · Gregory Biedermann, MD (1) · Heath Skinner, MD, PhD (1) · Jacques Tortochaux (1) · Jared Weiss, MD (1) · Jason K Molitoris, MD, PhD (1) · Jean Bourhis (1) · Jospeh A Califano, MD (1) · Katharine A. Price, MD (1)
PMID 21831465, PMID 23083061, PMID 26186556, PMID 28498880, PMID 33963014, PMID 33989559, PMID 39636629, PMID 41570275, PMID 42032732, PMID 42200110
2009 (1), 2018 (1), U01CA183848 (1), U01CA287904 (1)